Sfoglia per AUTORE
ZIEMSSEN T
Collezione AOU San Luigi di Orbassano
Items : 3
Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years. in Multiple sclerosis journal - experimental, translational and clinical / Mult Scler J Exp Transl Clin. 2020 Dec 18;6(4):2055217320972137. doi: 10.1177/2055217320972137. eCol
2020
AOU San Luigi di Orbassano
AOU San Luigi di Orbassano
Horáková D; Boster A; Bertolotto A; Freedman MS; Firmino I; Cavalier SJ; Jacobs AK; Thangavelu K; Daizadeh N; Poole EM; Baker DP; Margolin DH; Ziemssen T;
Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies. in Neurology and therapy / Neurol Ther. 2020 Dec;9(2):443-457. doi: 10.1007/s40120-020-00191-7. Epub 2020 May 14.
2020
AOU San Luigi di Orbassano
AOU San Luigi di Orbassano
Bertolotto A; Arroyo R; Celius EG; Comi G; Havrdova EK; Honeycutt WD; Hunter SF; Izquierdo G; Kornek B; Miller T; Mitsikostas DD; Singer BA; Ziemssen T; Chung L; Daizadeh N; Afsar S; Hashemi L; Senior P;
Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings. in Frontiers in neurology / Front Neurol. 2019 Mar 22;10:253. doi: 10.3389/fneur.2019.00253. eCollection 2019.
2019
AOU San Luigi di Orbassano
AOU San Luigi di Orbassano
Barclay K; Carruthers R; Traboulsee A; Bass AD; LaGanke C; Bertolotto A; Boster A; Celius EG; de Seze J; Cruz DD; Habek M; Lee JM; Limmroth V; Meuth SG; Oreja-Guevara C; Pagnotta P; Vos C; Ziemssen T; Baker DP; Wijmeersch BV;